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Abstract
Background: Until the approval of dabigatran etexilate, treatment choices for stroke 
prevention in patients with atrial fibrillation (AF) were vitamin K antagonists (VKAs) 
or antiplatelet drugs. This analysis explored whether availability of non-vitamin K an-
tagonist oral anticoagulants post-dabigatran approval was associated with changing 
treatment patterns in China.
Methods: Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with 
Atrial Fibrillation (GLORIA-AF) collected data on antithrombotic therapy choices for pa-
tients with newly diagnosed nonvalvular AF at risk for stroke. In China, enrollment in phase 
1 (before dabigatran approval) and phase 2 (after dabigatran approval) occurred from 
2011 to 2013 and 2013 to 2014, respectively. Analyses were restricted to sites within 
China that contributed patients to both phases. The weighted average of the site-specific 
results was estimated for standardization. Sensitivity analyses used multiple regression.
Results: Thirteen sites participated in both phase 1 (419 patients) and phase 2 (276 
patients), 76.1% and 16.0% were known to be at high risk for stroke (CHA2DS2-VASc 
≥2) and bleeding (HAS-BLED ≥3); 55.5% were male. In phase 1, 16.7%, 61.6%, and 
21.7% of patients were prescribed oral anticoagulants (OACs), antiplatelet agents, and 
no treatment, respectively. Respective proportions were 26.4%, 40.6%, and 33.0% in 
phase 2. The absolute increase in the site-standardized proportion of patients pre-
scribed OACs after dabigatran availability was 9.9% (95% confidence interval [CI]: 
3.7%-16.0%). There was a standardized 17.3% (95% CI: −24.3% to −10.4%) absolute 
decrease in antiplatelet agent use.
Conclusions: There was an increase in OAC and decrease in antiplatelet agent pre-
scription since dabigatran availability in China. However, a large proportion of AF 
patients at risk for stroke remained untreated.
     |  409MA et Al.
1  | INTRODUC TION
Oral anticoagulant (OAC) therapy prevents ischemic stroke 
and reduces mortality in atrial fibrillation (AF) patients.1,2 OAC 
therapy is underused in Asian countries, including China.3,4 A 
2008-2009 report from the China National Stroke Registry 
demonstrated that 14% of nonvalvular AF patients with a 
history of ischemic stroke or transient ischemic attack were 
treated with a vitamin K antagonist (VKA) and 61% with an-
tiplatelet agents without VKAs, while 25% received no anti-
thrombotic therapy.5 Suggested explanations are a perceived 
higher baseline risk of anticoagulant-induced intracerebral hem-
orrhage among Chinese patients,6,7 a belief there is a low risk of 
ischemic stroke among Chinese AF patients8,9 and the potential 
for herb-drug interactions due to the high prevalence of herbal 
consumption.10 Warfarin interacts with many drugs and food in-
gredients, which may pose significant challenges in administra-
tion and monitoring.9 In addition, it has been stated that many 
patients in China lack access to good laboratory control for VKA 
therapy and therefore cannot be prescribed VKAs.11,12
Non-vitamin K antagonist oral anticoagulants (NOACs) have 
been suggested to be preferentially indicated over warfarin for 
Asian patients.11,13 Dabigatran etexilate was the first NOAC on the 
market. It was approved by the China Food and Drug Administration 
on 22 February 2013 for stroke prevention in AF patients and has 
been available in Hong Kong since 14 July 2011 (rivaroxaban, an-
other NOAC, was approved on 4 May 2015). New medicines must 
be registered with the China Food and Drug Administration prior 
to selection for inclusion within China's two major health insurance 
programs (rural and urban). In practice, dabigatran was included in 
the National Drug Reimbursement List in 2017, the first update of 
the list since 2009.
Several guidelines and consensus documents have been pub-
lished in China to optimize anticoagulation therapy for stroke pre-
vention in patients with AF14,15 and, following the introduction of 
NOACs, more educational programs have been conducted.3
Given the obstacles to VKA use in China, the introduction of 
 dabigatran (along with the contemporaneous expert consensus and ed-
ucational programs) can be expected to have increased the proportion 
of patients prescribed OACs for stroke prevention in AF. The objective 
of this analysis was to explore whether availability of NOACs was as-
sociated with changing treatment patterns in China by comparing the 
proportion of treated patients between pre- and post-dabigatran ap-
proval periods.
2  | METHODS
2.1 | Study design, participants, and setting
The design of the Global Registry on Long-Term Oral Antithrombotic 
Treatment in Patients with Atrial Fibrillation (GLORIA-AF) program 
has been reported previously.16 GLORIA-AF is an ongoing dis-
ease registry of newly diagnosed nonvalvular AF patients at risk 
for stroke, run in three separate phases (clinical trial identifier: 
NCT01468701). In phase 1, before approval of dabigatran, informa-
tion was collected before NOACs became available on the market. 
This initial phase used a cross-sectional approach, with no data col-
lected beyond the initial visit. From May 2011 (the date of the first 
patient in) until January 2013 (last patient in), 1063 eligible patients 
were enrolled, including 713 (67.1%) in China. VKA prescriptions 
were lower in China than other participating regions.12 Phase 2 
started when dabigatran was approved in each respective country. 
During this phase, baseline patient characteristics were collected 
regardless of OAC prescription, and patients initiating dabigatran 
were followed for up to 2 years. The OAC prescription rate was low 
in China.4 Phase 3, which is ongoing, was initiated when character-
istics of patients prescribed dabigatran and VKAs overlapped suffi-
ciently to allow comparative analyses; a 3-year follow-up is ongoing 
for all included patients.
GLORIA-AF sites were selected on the basis of confirmation that 
they diagnosed and followed up patients with AF, with no prerequisite 
for previous research experience. For a site to be eligible for inclusion, 
both dabigatran and VKAs must have been available or their avail-
ability must have been foreseen. Sources for site identification in-
cluded professional directories, referrals from selected investigators 
and national coordinators, and sites that had previously worked with 
the study sponsor. Different health-care settings (general practices, 
specialist offices, community hospitals, university hospitals, etc) were 
included worldwide. Physicians were encouraged to consecutively 
enroll unselected consenting patients meeting the eligibility criteria. 
GLORIA-AF was performed in accordance with the provisions of the 
Declaration of Helsinki, and the protocol and procedures were ap-
proved by the European Medicines Agency, as well as relevant in-
stitutional review boards and ethics committees where required. All 
patients provided written informed consent before entering the reg-
istry. Patients were cared for by routine standard practice and were 
not required to be prescribed any specific treatment. In both phases 
1 and 2, eligible patients were aged ≥18 years with newly diagnosed 
(<3 months) nonvalvular AF at risk for stroke (CHA2DS2-VASc score 
District, Beijing 100029, P.R. China.
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≥1). Patients with mechanical heart valves, prior VKA therapy for 
>60 days, life expectancy ≤1 year at enrollment, medical conditions 
other than AF for which long-term use of VKAs is indicated, and AF 
due to a generally reversible cause were excluded.
This analysis focuses on eligible patients from phases 1 and 2 of 
GLORIA-AF, enrolled by sites from mainland China that had patients 
included in both phases. Patients were enrolled in phase 1 from 
December 2011 to January 2013 and in phase 2 from September 
2013 to June 2014. Database lock for the analysis was done in 
March 2015. In this exploratory analysis, no a priori sample size 
calculation was performed, and all eligible patients were included.
2.2 | Variables
Baseline characteristics and antithrombotic treatment strategy 
were collected using electronic case report forms at the time of 
the enrollment (baseline) visit. The main outcome for this analysis 
was prescription of an OAC, excluding patients prescribed multiple 
OACs, but including patients prescribed an OAC in association with 
an antiplatelet drug. Prescription of an antiplatelet drug alone was a 
secondary outcome. Antithrombotic treatment strategy was defined 
based on antithrombotic treatments prescribed for long-term use at 
the time of the baseline visit, or any antithrombotic treatments that 
the patient was already using at the time of the baseline visit and 
would continue using long term.
Baseline patient characteristics included demographic and 
clinical data, AF characteristics, medical history, and selected con-
comitant treatments. Labile international normalized ratio was not 
collected at baseline; a modified hypertension, abnormal renal func-
tion, abnormal liver function, stroke (prior), bleeding (prior), labile in-
ternational normalized ratio, elderly (age >65 years), prior alcohol or 
drug usage history, medication usage predisposing to bleeding (anti-
platelet agents, nonsteroidal anti-inflammatory drugs) (HAS-BLED) 
score not considering labile international normalized ratio was used.
Potential confounders in the association between the phase 
of the study and antithrombotic prescriptions considered were 
as follows: risk scores for stroke (CHA2DS2-VASc) and bleeding 
(modified HAS-BLED), age, sex, body mass index, AF character-
istics (categorization as asymptomatic, minimally symptomatic, or 
symptomatic; and type as permanent, persistent, or paroxysmal 
AF), history of thromboembolic disease (stroke), cardiovascular 
history (myocardial infarction, coronary artery disease, congestive 
heart failure/left ventricular dysfunction, hypertension), history of 
bleeding events, other medical history (diabetes mellitus, chronic 
gastrointestinal disease), enrollment site, and month of enrollment.
2.3 | Statistical methods
The objective was to assess the changes in antithrombotic treatment 
patterns after dabigatran availability, which involved comparing pat-
terns during phases 1 and 2 of the GLORIA-AF registry program.
To avoid bias due to different sites participating in the study 
phases, analyses were restricted to sites from mainland China (the 
main country enrolling patients in phase 1) enrolling patients in both 
phases 1 and 2.
As site participation may have differed between phases 1 and 
2 of the study, and sites may have differed in their antithrombotic 
prescription patterns, the main analysis involved within-site compar-
isons with standardization across sites.17 Standardization involved 
taking a weighted average of the site-specific results, weighting 
by the total number of patients enrolled by each site during both 
phases.
Patient characteristics were described according to phase. We 
conducted a sensitivity analysis using log-binomial regression18 to 
account for phase, site, and characteristics imbalanced between 
phases 1 and 2. Log-binomial regression provides probability (in 
this case, antithrombotic treatment prescription) and probabil-
ity ratios (in this case, the ratio between phase 2 and phase 1). 
Imbalanced characteristics were defined as any variable for which 
the absolute value of the standardized difference19 between phase 
1 and phase 2 was higher than 10%. The standardized difference 
compared the difference in means in units of the pooled standard 
deviation.
For multiple regression, missing values were treated as an ab-
sence of the considered risk factor; standardized differences were 
also assessed after single imputation for missing values.
To avoid confusion between the use of “standardized” for imbal-
ance diagnosis (standardized difference) and of “standardization” as 
our main analysis approach controlling for site effects, “site-stan-
dardized” will be used in the remainder of the article to describe the 
latter.
The proportion of OAC use during baseline was also described 
according to the month of baseline visit for both phases 1 and 2 
to assess underlying time trends. In addition, a log-binomial model 
estimating the association between time and OAC use was fitted 
to the subset of patients enrolled in phase 1, adjusting for site 
and patient characteristics found to be imbalanced between 
study phases. A potential phase 2 trend was not explored by mul-
tivariable modeling, since the focus was on assessing the extent 
to which the change in OAC use observed in phase 2 could be 
explained by a prescription trend before dabigatran availability. 
Inclusion of both phase and time as predictors in a multiple regres-
sion was not reasonable because of high multicollinearity between 
time and phase.
3  | RESULTS
3.1 | Participants
Treatments prescribed and baseline characteristics of overall pa-
tients in phase 112 and phase 24,20 are described elsewhere. In 
mainland China, 25 sites enrolled 713 eligible patients in phase 1 
and 45 sites enrolled 1018 eligible patients in phase 2. Thirteen sites 
     |  411MA et Al.
contributed to both phase 1 (419 patients enrolled) and phase 2 (276 
patients enrolled) (Figure 1).
Sites participating only in phase 1 had fewer eligible patients 
per site (24.5 ± 12.5 on average vs 32.2 ± 11.6 patients per site in 
phase 1 for sites contributing to both phases). The average number 
of eligible phase 2 patients per site was 23.2 ± 30.2 for sites par-
ticipating in phase 2 only and 21.2 ± 11.8 for sites participating in 
both phases. The rate of OAC prescription in phase 1 was higher for 
sites participating in phase 1 only (26% vs 17% for sites participating 
in both phases), possibly due to patients having a lower HAS-BLED 
score (1.2 ± 0.98 vs 1.6 ± 0.95, respectively). In phase 2, the converse 
was observed, with a lower proportion of OAC prescriptions for sites 
participating in phase 2 only compared with those participating in 
both phases (19% vs 26%, respectively), despite similar HAS-BLED 
scores (1.2 ± 0.88 vs 1.2 ± 0.95, respectively).
The analyses restricted to sites contributing to both phases in-
volved 695 patients, enrolled from 13 sites located in Beijing (n = 5, 
41% of patients); Shanghai (n = 3, 21%); Guangzhou (n = 2, 10%); 
Nanjing, Hangzhou, and Changsha (one site each; 11%, 10%, and 6%, 
respectively). In both phases combined, most patients were enrolled 
in university hospitals (489 patients, 70%), with community hospitals 
(119, 17%), and specialist offices (87, 13%) being less common. Most 
patients were treated by a cardiologist (681, 98%).
3.2 | Patient characteristics
There were signs of imbalance (standardized difference >10%) in 
some patient characteristics between phase 1 (pre-dabigatran ap-
proval) and phase 2: category of AF (65% of patients in phase 1 and 
44% in phase 2 were symptomatic; standardized difference: +43%), 
known high-bleeding risk (modified—not considering labile interna-
tional normalized ratio—HAS-BLED ≥3), body mass index, known 
prior bleed, congestive heart failure, gastrointestinal disease, and 
prior myocardial infarction (Table 1).
3.3 | Antithrombotic treatment strategies
Figure 2 presents the proportion of patients prescribed OACs per 
month. Sites were not active in China between February and August 
2013 (transition period between phases 1 and 2). In phase 1, 17% 
F I G U R E  1   Flow chart of patients considered for the analysis. AP, antiplatelet agent; OAC, oral anticoagulant
GLORIA-AF phase 1
1100 patients enrolled
1063 eligible
GLORIA-AF phase 2
15 641 patients enrolled
15 092 eligible
Mainland China
713 patients
25 sites
Mainland China
1018 patients
45 sites
Sites in both phases
419 patients
13 sites
Sites in both phases
276 patients
13 sites
Antithrombotic: 
OAC: 70 patients
AP: 258 patients
None: 91 patients
Antithrombotic: 
OAC: 73 patients
AP: 112 patients
None: 91 patients
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of patients were prescribed OACs; this proportion varied from 0% 
to 41% depending on the site. In phase 2, the proportion was 26%, 
varying from 0% to 67%. In addition, site contributions were differ-
ent according to phase; at the extremes, one site contributed 12% of 
phase 1 patients vs 7% of phase 2 patients, and another site contrib-
uted 8% vs 15%, respectively. Enrollment site was therefore associ-
ated with both phase and treatment prescribed.
Table 2 and Figure 3 present the crude and site-standardized pro-
portions of treatments prescribed, along with site-standardized esti-
mates of the difference in proportions between phase 2 and phase 1 as 
well as the ratio of proportions. From phase 1 to phase 2, standardizing 
by site, the proportion of patients receiving OACs increased by 10 per-
centage points (95% confidence interval [CI]: 4-16), corresponding to a 
relative increase of (0.272/0.173 − 1) = 57% (95% CI: 19%-107%).
The increase in OAC use came with a decrease (−17%) in anti-
platelet drug use alone but also an increase (+7%) in the proportion 
of untreated patients.
By definition, no NOAC was available in phase 1 (before avail-
ability of dabigatran) and all OAC use corresponded to VKA use. In 
phase 2, eight patients were prescribed NOACs, constituting 2% of 
all phase 2 patients, in addition to 24% prescribed VKAs.
3.4 | Sensitivity analyses
When controlling for site, body mass index, bleeding risk (modi-
fied HAS-BLED), category of AF, history of bleeding, myocardial 
infarction, congestive heart failure, and chronic gastrointestinal 
disease in a multiple log-binomial regression model, OAC use 
increased by 47% in phase 2 (95% CI: 10%-97%) (Table 3). This 
increase was 57% (95% CI: 19%-107%) in the main analysis stand-
ardizing by site.
Differences between phase 2 and phase 1 of the study may be 
related to a temporal trend that predates dabigatran availability. In 
TA B L E  1   Patient characteristics according to study phase
 Phase 1 (pre-dabigatran) n = 419 Phase 2 (post-dabigatran) n = 276 Standardized difference
Demographics
Age, mean (SD) 68.1 (11.75) 67.2 (11.71) 0.08
Female, n (%) 185 (44.2) 124 (44.9) −0.02
BMI, mean (SD) 23.8 (3.58) 24.5 (3.75) −0.19
Risk scores, n (%)
CHA2DS2-VASc ≥2 318 (75.9) 211 (76.4) −0.01
Modified HAS-BLEDa  ≥3 63 (15.0) 24 (8.7) 0.20
AF characteristics, n (%)
Type of AF
Paroxysmal 276 (65.9) 182 (65.9) −0.00
Persistent 139 (33.2) 90 (32.6) 0.01
Permanent 4 (1.0) 4 (1.4) −0.05
Category of AF
Asymptomatic 66 (15.8) 60 (21.7) −0.15
Minimally symptomatic 81 (19.3) 95 (34.4) −0.35
Symptomatic 272 (64.9) 121 (43.8) 0.43
Medical history, n (%)
Stroke 43 (10.3) 36 (13.0) −0.09
Bleeding 23 (5.5) 7 (2.5) 0.15
Myocardial infarction 27 (6.4) 27 (9.8) −0.12
Coronary artery disease 115 (27.4) 75 (27.2) 0.01
Congestive heart failureb  86 (20.5) 73 (26.4) −0.14
Hypertension 300 (71.6) 192 (69.6) 0.04
Diabetes mellitus 83 (19.8) 57 (20.7) −0.02
Gastrointestinal disease 40 (9.5) 17 (6.2) 0.13
Abbreviations: AF, atrial fibrillation; BMI, body mass index; HAS-BLED, hypertension, abnormal renal function, abnormal liver function, stroke 
(prior), bleeding (prior), labile international normalized ratio, elderly (age >65 y), prior alcohol or drug usage history, medication usage predisposing to 
bleeding (antiplatelet agents, nonsteroidal anti-inflammatory drugs); SD, standard deviation.
aPatients with missing HAS-BLED (n = 13) were considered at low risk. 
bCongestive heart failure/left ventricular dysfunction. 
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Figure 2, no clear trend is apparent during either phase 1 or 2. A time 
trend could be masked by variations in patient characteristics over 
time. When predicting OAC use over time during phase 1, controlling 
for site, body mass index, bleeding risk (modified HAS-BLED), cat-
egory of AF, history of bleeding, myocardial infarction, congestive 
heart failure, and chronic gastrointestinal disease in a multiple 
log-binomial regression model (Table 3, column 3), there was, how-
ever, no indication of a linear increase in OAC prescriptions over time 
(probability ratio of OAC prescription from one month to the next: 
0.94, 95% CI: 0.86-1.01).
4  | DISCUSSION
The principal study findings are as follows: (a) OAC use increased in 
China after NOACs became available; (b) this increase is only partly 
driven by an increase in NOAC use; and (c) in parallel, antiplatelet 
agent use decreased.
When considering available guidelines, OACs,21 and particularly 
NOACs, are becoming the standard of care for stroke prevention 
in AF worldwide; they are already recommended in preference to 
VKAs in various guidelines.2,22 The 2016 Chinese expert consensus 
on the management of AF in the elderly population recommends 
using NOACs to treat older AF patients (≥65 years), especially pa-
tients who cannot tolerate warfarin, patients who had bleeding after 
warfarin treatment, or those who have unstable international nor-
malized ratio.23
In accordance with this trend, analyses from GLORIA-AF after 
dabigatran availability (phase 2 of the registry program) have shown 
that uptake of NOACs was more prevalent than uptake of VKAs, 
except in Asia, where 28% of patients received VKAs and 28% 
NOACs.20 Country-specific analyses4 indicate that oral anticoagu-
lation use in mainland China is even lower than in other Asian loca-
tions, with 15% of patients prescribed VKAs and 6% a NOAC.
Low NOAC uptake may be related to availability status in China: 
while dabigatran has been available in China since February 2013, 
F I G U R E  2   Enrolled patient numbers and crude proportion of OAC use over time. Numbers in the lines correspond to the number of 
patients enrolled in each month. OAC, oral anticoagulant
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TA B L E  2   Antithrombotic treatment and study phase
Treatment
Crude N (%)
Phase 1  
(pre-dabigatran) 
n = 419
Phase 2  
(post-dabigatran) 
n = 276
OAC 70 (16.7) 73 (26.4)
Of which NOAC — 8 (2.3)
Antiplatelet agent 258 (61.6) 112 (40.6)
None 91 (21.7) 91 (33.0)
Abbreviations: OAC, oral anticoagulant (±antiplatelet drug); NOAC, 
non-vitamin K antagonist oral anticoagulant (±antiplatelet drug).
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it was listed in the National Drug Reimbursement List in 2017, after 
the GLORIA-AF phase 2 study period. Another explanation may be 
that, since the enrollment period in phase 2 was relatively short 
(10 months) in China (all locations combined, enrollment in phase 
2 extended from December 2011 to December 2014), physicians 
had insufficient time to adapt to the new treatment availabilities.
Our analyses are consistent with an increase of OAC use and a de-
crease in antiplatelet drug use after dabigatran availability. Considering 
that after NOACs became available, guidelines and consensus on OAC 
treatment optimization have been published and more educational 
programs have been conducted,3 this trend is perhaps not surpris-
ing. Other studies in the United States,24 Denmark,25 Australia,26 and 
Korea27 have reported similar trends, although some US studies also 
reported no increase in OAC prescriptions overall, with an increase 
in NOAC uptake being compensated for by a decrease in VKA use.28
Our observations are concordant with an analysis based on the 
Chinese Atrial Fibrillation Registry, involving 20 tertiary and 12 non-
tertiary hospitals in Beijing, which reveals considerable variability in 
OAC use across sites. The Chinese Atrial Fibrillation Registry also 
reported an increase in OAC use over time, especially in the period 
following dabigatran availability. In patients with CHA2DS2-VASc 
≥2, OAC use increased from 30.2% to 38.1% from August 2011 to 
August 2013, and to 57.7% by August 2014.3
In line with other registries, this analysis from GLORIA-AF in-
dicates that OAC use increased in China after dabigatran approval. 
Nonetheless, although all patients in the GLORIA-AF registry 
had a CHA2DS2-VASc score of ≥1, and 76% in this analysis had 
a CHA2DS2-VASc score ≥2, many patients were treated with an-
tiplatelet drugs alone (40.6% after dabigatran approval) or were 
not treated (33.0%). In this analysis, the increase in OAC use after 
dabigatran approval (+10%) was only partially explained by NOAC 
prescriptions alone (+2%). It is possible that, in a setting where 
NOACs were not covered by medical insurance, economic fac-
tors may have had a greater influence on what was prescribed. 
Nonetheless, NOAC approval may have had an indirect role, trig-
gering guideline updates and increasing the awareness of optimal 
management of stroke prevention in AF.
4.1 | Limitations
Some limitations should be considered. The number of patients avail-
able for the analyses was modest, limiting our ability to adjust for 
confounders and identify time trends. As phase 2 of the study started 
when dabigatran was approved in each respective country, the enroll-
ment period in phase 2 was relatively short (10 months) in China where 
dabigatran was approved in February 2013 (compared with December 
2011 to December 2014 for all locations combined). This may have 
limited the number of patients enrolled in China. In addition, analyses 
were restricted to mainland China. As such, our results illustrate the 
F I G U R E  3   Site-standardized antithrombotic treatment prescription probability differences and probability ratios from phase 1 to phase 2. 
AP, antiplatelet agent; ATT, antithrombotic treatment; CI, confidence interval; OAC, oral anticoagulant
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changing pattern of use of OACs and NOACs under the specific cir-
cumstances prevailing in China. Restriction to a single country has the 
advantage of controlling more effectively for geographic and cultural 
differences. In contrast, the findings may not be applicable to other 
Asian countries, especially those where reimbursement was possible 
shortly after NOAC approval. Furthermore, the 13 sites included in 
the present analysis may not be representative of all Chinese patients. 
The majority of patients were enrolled by university hospitals, which 
may have been quicker to change prescription behaviors. The change 
in the whole country may have been less marked. However, the trends 
observed in this analysis from phases 1 and 2 of the GLORIA-AF reg-
istry program, adjusting for enrolling sites, are robust in our sensitivity 
analyses, consistent with other reported evidence from China5 and in 
line with expected evolutions in antithrombotic use after the introduc-
tion of NOACs and guideline updates.
5  | CONCLUSION
The patterns observed in patients enrolled in GLORIA-AF in mainland 
China are consistent with an increase in the proportion of patients pre-
scribed OACs since dabigatran became available. In parallel, the rate 
of antiplatelet prescriptions showed a decrease following  dabigatran 
availability and is in line with published guidelines. Despite the increase 
in oral anticoagulation use since dabigatran availability, a large propor-
tion of patients remain untreated, or treated with antiplatelet only.
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